Our partnering strategy
We are developing a platform that has the potential to transform the lives of people with cancer and other severe diseases. We are committed to develop our technology to maximize its potential beyond the core indications.
We are actively seeking collaborations around the world to leverage the therapeutic potential of our platform fully. Specific areas of interest include:
- Combination of MVX-ONCO with Immune Checkpoint Inhibitors in specific indications
- Novel technologies which may enhance key features of cancer immunotherapies
- Novel and impactful applications of our drug delivery platform
Are you interested in partnering with MaxiVAX?
Please contact us at email@example.com
Our current partners
Since August 2020, MaxiVAX entered into a strategic manufacturing agreement with Minaris Regenerative Medicine for future commercial production. This will allow MaxiVAX to develop its GMP validated and scalable manufacturing process towards market access. Minaris RM is a leading global Contract Manufacturing and Development Organization (CDMO), pioneer in the field of cell and gene therapy and has a presence worldwide.
We are collaborating with the University Hospital of Geneva to develop out platform and evaluate safety and efficacy of our personalized immunotherapy in solid tumors.